Cosmos Health launches nanotechnology program for supplements

CHICAGO - Cosmos Health Inc. (NASDAQ:COSM) announced Friday the initiation of a new research and development program that will use nanotechnology to enhance the effectiveness of ingredients in its dietary supplements. The micro-cap company, valued at approximately $28 million, has seen its stock surge 112% over the past six months despite experiencing significant volatility.

The program builds upon the company’s proprietary technology developed during the creation of its CCX Hydrogel platform for bioactive delivery. Cosmos Health is now developing plant-based extract-loaded phytosomes for use in dietary supplements. According to InvestingPro data, the company faces profitability challenges with a gross profit margin of just 9.85%, significantly below industry averages.

According to the company’s press release, these nanostructured systems aim to improve the absorption, stability, and bioactivity of phytochemicals. The approach follows a sustainable, solvent-free process that emphasizes environmentally responsible formation of phytosomes.

"Our platform represents a promising step toward the development of sustainable, bioactive-enriched food technologies," said Greg Siokas, CEO of Cosmos Health, in the statement.

Dr. Panagiotis Zoumpoulakis, Head of Research & Development at Cosmos Health, added that the integration of nanotechnology enables the company to "explore the full potential of phytochemicals at the molecular level."

Cosmos Health, incorporated in 2009, is a vertically integrated healthcare group that owns several proprietary pharmaceutical and nutraceutical brands. The company manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union through its subsidiary Cana Laboratories S.A., which is licensed under European Good Manufacturing Practices and certified by the European Medicines Agency.

The company also distributes pharmaceuticals and parapharmaceuticals to retail pharmacies and wholesale distributors through subsidiaries in Greece and the UK.

In other recent news, Cosmos Health Inc. has been active in expanding its digital asset investments and business operations. The company has increased its Ethereum holdings with a recent purchase of $200,000, raising its total investment in the cryptocurrency to $2 million. This acquisition is part of Cosmos Health’s strategy to diversify its portfolio through its $300 million digital assets facility. Additionally, Cosmos Health has appointed Theodoros C. Karkantzos to its board of directors. Mr. Karkantzos brings over 15 years of experience in investment and business development, including roles in finance and asset management across Europe.

In other developments, Cosmos Health has expanded its Sky Premium Life brand into Kuwait. The subsidiary, SkyPharm S.A., has entered into an exclusive distribution agreement with Diyar United to market and sell its nutraceuticals in the region. This agreement includes a range of products such as collagen, vitamins, minerals, and herbal supplements. These recent actions reflect Cosmos Health’s ongoing efforts to diversify its investments and expand its market presence.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.